Treats active duodenal ulcer. ANDA 203957, held by Ajanta Pharma. Lansoprazole.
As of Nov 21, 2026, ANDA 203957 (Lansoprazole), held by Ajanta Pharma, was first approved by FDA on Oct 14, 2016, with 8 approved supplements and 0 published complete response letters.
Lansoprazole delayed-release capsules are proton pump inhibitors (PPIs) indicated for the: Treatment of active duodenal ulcer in adults. Eradication of H. pylori to reduce the risk of duodenal ulcer recurrence in adults. Maintenance of healed duodenal ulcers in adults. Treatment of active benign gastric ulcer in adults. Healing of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults. Risk reduction of NSAID-associated gastric ulcer in adults. Treatment of symptomatic gastroesophageal reflux disease (GERD) in adults and pediatric patients 1 year of age and older. Treatment of erosive esophagitis (EE) in adults and pediatric patients 1 year of age and older.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 14, 2016 | Original application | Approved | None posted |
| Lansoprazole15MG · capsule, delayed rel pellets;oral | Lansoprazole | Discontinued |
| Lansoprazole30MG · capsule, delayed rel pellets;oral | Lansoprazole | Discontinued |
| Aug 15, 2025 | Supplement 17Labeling · Standard review | Approved | None posted |
| Mar 12, 2025 | Supplement 15Labeling · Standard review | Approved | None posted |
| Nov 9, 2021 | Supplement 2Labeling · Standard review | Approved | None posted |
| Nov 9, 2021 | Supplement 5Labeling · Standard review | Approved | None posted |
| Nov 9, 2021 | Supplement 6Labeling · Standard review | Approved | None posted |
| Nov 9, 2021 | Supplement 7Labeling · Standard review | Approved | None posted |
| Nov 9, 2021 | Supplement 10Labeling · Standard review | Approved | None posted |
| Nov 9, 2021 | Supplement 12Labeling · Standard review | Approved | None posted |
| Oct 14, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters